Wallimann, Alexandra; Schenk, Mirjam (2023). IL-32 as a potential biomarker and therapeutic target in skin inflammation. Frontiers in immunology, 14(1264236), p. 1264236. Frontiers Research Foundation 10.3389/fimmu.2023.1264236
|
Text
fimmu-14-1264236.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
IL-32 is a recently described cytokine that performs a variety of functions under inflammatory conditions. Serum IL-32 has been shown to be elevated in several diseases, including type 2 diabetes, cancer, systemic lupus erythematosus, HIV infection, and atopic diseases including atopic dermatitis. There are nine different isoforms of IL-32, with IL-32γ being the most biologically active one. The following review summarizes the different roles of the various IL-32 isoforms in the context of skin inflammation, with a focus on atopic dermatitis.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology > Tumour Pathology 04 Faculty of Medicine > Service Sector > Institute of Pathology > Immunopathology 04 Faculty of Medicine > Service Sector > Institute of Pathology |
UniBE Contributor: |
Schenk, Mirjam |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
1664-3224 |
Publisher: |
Frontiers Research Foundation |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
21 Sep 2023 14:50 |
Last Modified: |
29 Oct 2023 02:23 |
Publisher DOI: |
10.3389/fimmu.2023.1264236 |
PubMed ID: |
37727785 |
Uncontrolled Keywords: |
CTCL IL-32 atopic dermatitis infection melanoma skin inflammation |
BORIS DOI: |
10.48350/186419 |
URI: |
https://boris.unibe.ch/id/eprint/186419 |
Actions (login required)
 |
Edit item |